 SAN FRANCISCO, Oct. 15, 2021 GLOBE NEWSWIRE -- Vir Biotechnology, Inc. Nasdaq: VIR today announced that three abstracts highlighting data from its hepatitis B clinical program and one health outcomes research abstract have been accepted for oral and poster presentation at the American Association for the Study of Liver Diseases AASLD The Liver Meeting, taking place virtually from November 12-15, 2021. 